Wikipedia -WSS

Wikipedia

author：fashion 2025-09-30 00:09:41 - browse：7

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： CRISPR base editing slashes cholesterol levels in monkeys

WSS

Hearing on Medicare drug price negotiation gets unusually heated

New oral drug delivery patch is modeled after octopus tentacles

Experts study whether long Covid risk adds up with each reinfection

Medical student insurance fails on mental health care coverage

It's been 20 years since Dolly the sheep. Where's my clone?

The Karikó problem: Lessons for funding basic research

entertainment

Wikipedia

Wikipedia

Hollywood unions extend contract negotiations for actors

Medicare innovation center doesn’t save money, experts say

In age of alternative facts, a scholarly course on calling out crap

Why are Kaiser Permanente staff considering a strike?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Ukraine and a new approach to mental health in war

Supreme Court strikes down use of affirmative action

The Karikó problem: Lessons for funding basic research

How one medical school became remarkably diverse

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

focus

Setback for rare diseases as Taysha Gene Therapies pulls back

Study points to new risk in gene therapy death of Terry Horgan

What will Novo Nordisk's VC do with its influx of cash?

Intarcia’s device

The Karikó problem: Lessons for funding basic research

CRISPR base editing slashes cholesterol levels in monkeys

focus

entertainment

explore

leisure time